––Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with Assembly Bio’s expertise and focus on antiviral R&D to ...
Assembly Biosciences reported positive Phase 1b results for ABI-4334 in chronic HBV, showing strong antiviral activity and favorable safety. Assembly Biosciences, Inc. has announced positive results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results